1. Home
  2. VMET vs DNA Comparison

VMET vs DNA Comparison

Compare VMET & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Versamet Royalties Corporation Common Stock

VMET

Versamet Royalties Corporation Common Stock

N/A

Current Price

$9.14

Market Cap

982.2M

Sector

N/A

ML Signal

N/A

Logo Ginkgo Bioworks Holdings Inc.

DNA

Ginkgo Bioworks Holdings Inc.

N/A

Current Price

$11.35

Market Cap

835.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VMET
DNA
Founded
2011
2008
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
982.2M
835.7M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
VMET
DNA
Price
$9.14
$11.35
Analyst Decision
Strong Buy
Sell
Analyst Count
3
3
Target Price
★ $14.31
$8.00
AVG Volume (30 Days)
232.1K
★ 2.6M
Earning Date
11-13-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 46.49
EPS
★ N/A
N/A
Revenue
N/A
★ $170,155,000.00
Revenue This Year
$155.17
N/A
Revenue Next Year
$37.11
$13.05
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$7.87
$5.37
52 Week High
$13.81
$18.22

Technical Indicators

Market Signals
Indicator
VMET
DNA
Relative Strength Index (RSI) 56.36 51.79
Support Level $9.10 $6.75
Resistance Level $9.87 $13.97
Average True Range (ATR) 0.35 1.26
MACD 0.11 -0.11
Stochastic Oscillator 83.67 41.15

Price Performance

Historical Comparison
VMET
DNA

About VMET Versamet Royalties Corporation Common Stock

Versamet Royalties Corp is a diversified metals royalty and streaming company with exposure to a range of resource royalties and streams including gold, silver, copper, zinc, graphite and uranium, across a variety of jurisdictions. The Company's operating segments are considered to be its individual royalties, streams and the Greenstone gold interest.

About DNA Ginkgo Bioworks Holdings Inc.

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Share on Social Networks: